NasdaqCM · Biotechnology

Jade Biosciences (JBIO)

Stock, pipeline and biotech catalyst intelligence

Analyst view

Strong Buy+134.9%

$50.13 average target

$21.34+0.11 (+0.5%)Latest market snapshot · Yahoo Finance

Market cap$1.36B

Cash$461.2M

Quarterly burn$24.1M

Pipeline assets3

Short float16.7%

Market expectations

Analyst Ratings & Price Targets

Data may be delayed

Street view at a glance

The average target implies 134.9% upsideTargets are estimates—not guarantees—and can change after company updates.

$50.13Average target

Wall Street consensus

Strong BuyBased on 8 analyst opinions

10ratings

Buy 10Hold 0Sell 0

Price-target range

$50.13

+134.9%

Low $40.00High $77.00

CurrentAverage

Bear case$40.00+87.4%

Base case$50.13+134.9%

Bull case$77.00+260.8%

Analyst coverage8published opinions

Bullish share100%buy recommendations

Target spread$37low-to-high dispersion

Consensus score1.01.0 is strongest

Recommendation mix

Current rating breakdown

10 tracked ratings

Company profile

About Jade Biosciences

Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.

Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.

Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.